Abstract
EARLY THIS YEAR SAW THE FORMAtion of a new company, Johannesburg-based Oxyrane, to commercialize research into epoxide hydrolase biocatalysis. The technology was developed by a team led by Adri Botes within a partnership between the University of the Free State and CSIR, an industrial research institute. Oxyrane is a privately funded spin-off from these institutions. Now the company is working hard on two fronts. Backed by several patents, it is commercializing the resulting technology as a cost-effective green route for the production of chiral epoxides. It is also building in South Africa a technology-based company that is strong enough to compete on the world stage. From dipping a toe in the water at the June ChemSpec specialty chemical exhibition in Dusseldorf, Michael Campbell, chief executive officer, and Robin Mitra, process operations director, will spearhead the company's debut at the CPhI pharmaceutical ingredients show in Madrid next month. They will be presenting a market-ready technology ...
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
